WGU D775 Objective Assessment 2025 — (2 Set Exams)
Questions with Verified Answers | Instant PDF
Download WITH RATIONALES || 100% GUARANTEED
PASS!! <LATEST VERSION>
,WGU D775: Advanced Pathopharmacological Foundations | Simulated Objective
Assessment
Instructions: This assessment tests your ability to synthesize advanced
pathophysiological concepts with pharmacological management. Select the single
best Correct answer
Section 1: Complex Multisystem Disorders & Pharmacotherapeutics
1. A 58-year-old patient with a long history of Type 2 Diabetes Mellitus and
hypertension presents with progressive fatigue, edema, and a serum creatinine
of 2.8 mg/dL (eGFR 22 mL/min). The provider diagnoses diabetic nephropathy.
Which class of antihypertensive medication is considered a first-line therapy for
this patient, due to its renoprotective effects that extend beyond blood
pressure control?
A. Loop diuretics (e.g., furosemide)
B. Thiazide diuretics (e.g., hydrochlorothiazide)
C. Angiotensin-Converting Enzyme Inhibitors (ACE-I) (e.g., lisinopril)
D. Dihydropyridine calcium channel blockers (e.g., amlodipine)
Correct - Correct answer-: : C. Angiotensin-Converting Enzyme Inhibitors (ACE-I)
Rationale: ACE inhibitors (and ARBs) are first-line for diabetic nephropathy. They
reduce intraglomerular pressure by dilating the efferent arteriole, thereby
decreasing proteinuria and slowing the progression of renal disease via
mechanisms independent of their antihypertensive effect.
2. A patient with heart failure with reduced ejection fraction (HFrEF) is started
on a quadruple therapy guideline-directed medical therapy (GDMT). This
regimen includes a beta-blocker, an MRA, an SGLT2 inhibitor, and which other
foundational agent that directly targets the neurohormonal RAAS pathway?
A. Digoxin
B. An Angiotensin Receptor-Neprilysin Inhibitor (ARNI) like sacubitril/valsartan
C. Isosorbide dinitrate/hydralazine
D. Ivabradine
,Correct - Correct answer-: : B. An Angiotensin Receptor-Neprilysin Inhibitor
(ARNI)
Rationale: Current guidelines for HFrEF prioritize an ARNI (or an ACE-I/ARB if ARNI
is not tolerated) as a cornerstone of therapy. ARNIs provide dual action: blocking
the angiotensin II receptor and inhibiting neprilysin, which increases beneficial
natriuretic peptides, leading to vasodilation and reduced fibrosis.
3. In the management of acute exacerbation of COPD, systemic corticosteroids
are a mainstay. What is the primary pathophysiological rationale for their use in
this context?
A. To eliminate the bacterial infection causing the exacerbation.
B. To reduce airway inflammation and edema, thereby decreasing airflow
limitation.
C. To stimulate surfactant production and prevent alveolar collapse.
D. To act as a potent bronchodilator by relaxing smooth muscle.
Correct - Correct answer-: : B. To reduce airway inflammation and edema.
Rationale: While bronchodilators (beta-agonists, anticholinergics) are key for
smooth muscle relaxation, corticosteroids target the underlying inflammatory
component of a COPD exacerbation. They suppress the influx of inflammatory
cells and the release of cytokines, reducing mucosal edema and secretions to
improve airflow.
Section 2: Pharmacogenomics & Adverse Drug Reactions
4. Prior to initiating therapy with abacavir for HIV, screening for the HLA-B*5701
allele is mandatory. A patient who tests positive for this allele should not
receive abacavir due to a high risk of:
A. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
B. Hepatotoxicity
C. Hypersensitivity Reaction (which can be severe and fatal)
D. QT prolongation and Torsades de Pointes
Correct - Correct answer-: : C. Hypersensitivity Reaction
Rationale: The association between HLA-B*5701 and abacavir hypersensitivity
reaction (HSR) is a classic example of clinical pharmacogenomics. Screening
prevents this potentially life-threatening, immune-mediated reaction
characterized by fever, rash, respiratory symptoms, and gastrointestinal distress.
, 5. A patient on long-term warfarin therapy has been stable with an INR of 2.0-
3.0. They are prescribed sulfamethoxazole/trimethoprim for a urinary tract
infection. The nurse anticipates that this will likely cause the patient's INR to
____, increasing the risk of _____.
A. Increase; bleeding
B. Decrease; clotting
C. Increase; clotting
D. Decrease; bleeding
Correct - Correct answer-: : A. Increase; bleeding
Rationale: Sulfamethoxazole/trimethoprim is a strong inhibitor of the CYP2C9
enzyme, which is responsible for metabolizing the more active S-enantiomer of
warfarin. Inhibition leads to increased warfarin levels and a elevated INR, thereby
increasing the risk of hemorrhage.
Section 3: Oncology & Targeted Therapies
6. A patient with metastatic non-small cell lung cancer (NSCLC) is found to have
a tumor positive for an EGFR exon 19 deletion mutation. What is the most
appropriate first-line targeted therapy?
A. Pembrolizumab (an anti-PD-1 immune checkpoint inhibitor)
B. Osimertinib (a third-generation EGFR tyrosine kinase inhibitor)
C. Trastuzumab (an anti-HER2 monoclonal antibody)
D. Bevacizumab (an anti-VEGF monoclonal antibody)
Correct - Correct answer-: : B. Osimertinib
Rationale: For NSCLC with activating EGFR mutations (like exon 19 deletions or
L858R), EGFR tyrosine kinase inhibitors (TKIs) are first-line. Osimertinib is a third-
generation TKI preferred due to its efficacy and ability to penetrate the CNS. It is
superior to earlier-generation TKIs like erlotinib.
7. A patient receiving combination chemotherapy with bleomycin is closely
monitored for pulmonary toxicity. What is the primary pathophysiological
mechanism of bleomycin-induced lung injury?
A. Capillary leak syndrome causing non-cardiogenic pulmonary edema.
B. Direct endothelial damage leading to pulmonary hypertension.
C. Generation of reactive oxygen species causing oxidative injury to pneumocytes.
D. Allergic hypersensitivity leading to eosinophilic pneumonia.
Questions with Verified Answers | Instant PDF
Download WITH RATIONALES || 100% GUARANTEED
PASS!! <LATEST VERSION>
,WGU D775: Advanced Pathopharmacological Foundations | Simulated Objective
Assessment
Instructions: This assessment tests your ability to synthesize advanced
pathophysiological concepts with pharmacological management. Select the single
best Correct answer
Section 1: Complex Multisystem Disorders & Pharmacotherapeutics
1. A 58-year-old patient with a long history of Type 2 Diabetes Mellitus and
hypertension presents with progressive fatigue, edema, and a serum creatinine
of 2.8 mg/dL (eGFR 22 mL/min). The provider diagnoses diabetic nephropathy.
Which class of antihypertensive medication is considered a first-line therapy for
this patient, due to its renoprotective effects that extend beyond blood
pressure control?
A. Loop diuretics (e.g., furosemide)
B. Thiazide diuretics (e.g., hydrochlorothiazide)
C. Angiotensin-Converting Enzyme Inhibitors (ACE-I) (e.g., lisinopril)
D. Dihydropyridine calcium channel blockers (e.g., amlodipine)
Correct - Correct answer-: : C. Angiotensin-Converting Enzyme Inhibitors (ACE-I)
Rationale: ACE inhibitors (and ARBs) are first-line for diabetic nephropathy. They
reduce intraglomerular pressure by dilating the efferent arteriole, thereby
decreasing proteinuria and slowing the progression of renal disease via
mechanisms independent of their antihypertensive effect.
2. A patient with heart failure with reduced ejection fraction (HFrEF) is started
on a quadruple therapy guideline-directed medical therapy (GDMT). This
regimen includes a beta-blocker, an MRA, an SGLT2 inhibitor, and which other
foundational agent that directly targets the neurohormonal RAAS pathway?
A. Digoxin
B. An Angiotensin Receptor-Neprilysin Inhibitor (ARNI) like sacubitril/valsartan
C. Isosorbide dinitrate/hydralazine
D. Ivabradine
,Correct - Correct answer-: : B. An Angiotensin Receptor-Neprilysin Inhibitor
(ARNI)
Rationale: Current guidelines for HFrEF prioritize an ARNI (or an ACE-I/ARB if ARNI
is not tolerated) as a cornerstone of therapy. ARNIs provide dual action: blocking
the angiotensin II receptor and inhibiting neprilysin, which increases beneficial
natriuretic peptides, leading to vasodilation and reduced fibrosis.
3. In the management of acute exacerbation of COPD, systemic corticosteroids
are a mainstay. What is the primary pathophysiological rationale for their use in
this context?
A. To eliminate the bacterial infection causing the exacerbation.
B. To reduce airway inflammation and edema, thereby decreasing airflow
limitation.
C. To stimulate surfactant production and prevent alveolar collapse.
D. To act as a potent bronchodilator by relaxing smooth muscle.
Correct - Correct answer-: : B. To reduce airway inflammation and edema.
Rationale: While bronchodilators (beta-agonists, anticholinergics) are key for
smooth muscle relaxation, corticosteroids target the underlying inflammatory
component of a COPD exacerbation. They suppress the influx of inflammatory
cells and the release of cytokines, reducing mucosal edema and secretions to
improve airflow.
Section 2: Pharmacogenomics & Adverse Drug Reactions
4. Prior to initiating therapy with abacavir for HIV, screening for the HLA-B*5701
allele is mandatory. A patient who tests positive for this allele should not
receive abacavir due to a high risk of:
A. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
B. Hepatotoxicity
C. Hypersensitivity Reaction (which can be severe and fatal)
D. QT prolongation and Torsades de Pointes
Correct - Correct answer-: : C. Hypersensitivity Reaction
Rationale: The association between HLA-B*5701 and abacavir hypersensitivity
reaction (HSR) is a classic example of clinical pharmacogenomics. Screening
prevents this potentially life-threatening, immune-mediated reaction
characterized by fever, rash, respiratory symptoms, and gastrointestinal distress.
, 5. A patient on long-term warfarin therapy has been stable with an INR of 2.0-
3.0. They are prescribed sulfamethoxazole/trimethoprim for a urinary tract
infection. The nurse anticipates that this will likely cause the patient's INR to
____, increasing the risk of _____.
A. Increase; bleeding
B. Decrease; clotting
C. Increase; clotting
D. Decrease; bleeding
Correct - Correct answer-: : A. Increase; bleeding
Rationale: Sulfamethoxazole/trimethoprim is a strong inhibitor of the CYP2C9
enzyme, which is responsible for metabolizing the more active S-enantiomer of
warfarin. Inhibition leads to increased warfarin levels and a elevated INR, thereby
increasing the risk of hemorrhage.
Section 3: Oncology & Targeted Therapies
6. A patient with metastatic non-small cell lung cancer (NSCLC) is found to have
a tumor positive for an EGFR exon 19 deletion mutation. What is the most
appropriate first-line targeted therapy?
A. Pembrolizumab (an anti-PD-1 immune checkpoint inhibitor)
B. Osimertinib (a third-generation EGFR tyrosine kinase inhibitor)
C. Trastuzumab (an anti-HER2 monoclonal antibody)
D. Bevacizumab (an anti-VEGF monoclonal antibody)
Correct - Correct answer-: : B. Osimertinib
Rationale: For NSCLC with activating EGFR mutations (like exon 19 deletions or
L858R), EGFR tyrosine kinase inhibitors (TKIs) are first-line. Osimertinib is a third-
generation TKI preferred due to its efficacy and ability to penetrate the CNS. It is
superior to earlier-generation TKIs like erlotinib.
7. A patient receiving combination chemotherapy with bleomycin is closely
monitored for pulmonary toxicity. What is the primary pathophysiological
mechanism of bleomycin-induced lung injury?
A. Capillary leak syndrome causing non-cardiogenic pulmonary edema.
B. Direct endothelial damage leading to pulmonary hypertension.
C. Generation of reactive oxygen species causing oxidative injury to pneumocytes.
D. Allergic hypersensitivity leading to eosinophilic pneumonia.
